Revolutionizing Bioproduction: Stämm Unveils New High-Throughput Bioprocessor

Stämm's Innovative Approach to Bioproduction

Stämm has officially launched its High-Throughput Bioprocessor (HTB), an automated, single-use bioproduction platform designed for both adherent and suspension cells. This novel system is tailored to overcome the infrastructural limitations that frequently hinder research and development in biotechnological fields. By enabling scalability from 50 mL to 250 mL without hydrodynamic shear stress, it aims to lower capital expenditure (CAPEX) and nutrient media costs significantly.

The Need for Change in Bioproduction

Bioproduction currently faces a significant bottleneck, largely due to centralized and capital-intensive production infrastructures that are not well-suited for personalized manufacturing of innovative therapies in small batches. Stämm’s HTB directly addresses these challenges through its modular and flexible design. "We have developed this technology to close the logistical gap between scientific research and the wider availability of accessible treatments," explained Yuyo Llamazares, CEO of Stämm.

Features of the High-Throughput Bioprocessor

At the heart of the HTB is the Bubble-Free Bioreactor (BFB), a customizable, 3D-printed consumable that eliminates the need for traditional impellers. This innovative design ensures that nutrient transport and gas exchange occur through laminar flow, mimicking the capillary networks found in living tissues. The absence of bubbling or anti-foam agents also significantly reduces turbulence and hydrodynamic shear stress, thereby protecting delicate cell populations.

In addition, the HTB supports continuous perfusion and integrated formulations for processes such as the differentiation of adherent cells. Moreover, automated sedimentation can be executed in suspension cultures, enhancing efficiency and productivity in the bioproduction process.

A Vision for Global Bioproduction

Stämm’s vision with the HTB is clear: to democratize access to innovative therapies regardless of geographic location. As Llamazares stated, "No patient should have to wait for treatment due to the limitations of centralized infrastructure, whether they are in Alaska, São Paulo, or Nairobi."

With the growing global demand for cell and gene therapies, the HTB is poised to ease the pressure on bioproduction capabilities. This platform could fundamentally change how biopharmaceuticals are developed and manufactured, facilitating quicker access to therapies for patients in underserved regions.

Availability and Future Developments

The HTB is currently available for process development under Research Use Only (RUO) applications. Stämm encourages pharmaceutical and biotech teams interested in preclinical production, CAR-T cell expansions, or workflows for monoclonal antibodies to reach out directly for more information. A thorough review of the technical specifications is ongoing, with limited partnerships available for early access.

Conclusion

The launch of Stämm’s High-Throughput Bioprocessor promises a transformative shift in bioproduction, emphasizing flexibility, accessibility, and efficiency. As the biopharmaceutical landscape continues to evolve, technologies like the HTB will play a crucial role in bridging the gap between groundbreaking research and real-world applications, ultimately enhancing patient care across the globe.